<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286581</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00008886</org_study_id>
    <nct_id>NCT04286581</nct_id>
  </id_info>
  <brief_title>Comparison of Ambu Auragain and I-Gel Supraglottic Airways in Adult Patients at an Ambulatory Surgery Center</brief_title>
  <official_title>Comparison of Ambu Auragain and I-Gel Supraglottic Airways in Adult Patients at an Ambulatory Surgery Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an I-gel laryngeal mask airway (LMA) has a
      higher oropharyngeal leak pressure compared to an Ambu Auragain in adult patients in an
      ambulatory surgery center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are scheduled for elective ambulatory surgery under general anesthesia will be
      randomized to one of two groups. Group 1 will receive an I-gel laryngeal mask airway (LMA)
      and group 2 will receive an Ambu Auragain LMA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who are scheduled for elective ambulatory surgery under general anesthesia will be randomized to one of two groups. Group 1 will receive an I-gel laryngeal mask airway (LMA) and group 2 will receive an Ambu Auragain LMA.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oropharyngeal Leak Pressure (OLP)</measure>
    <time_frame>4 hours</time_frame>
    <description>OLP will be measured immediately after insertion. This will be accomplished by closing the expiratory valve while keeping fresh gas flow at 3 liters/minute until equilibrium is reached. Pressure will be reported in cmH2O.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Placement</measure>
    <time_frame>4 hours</time_frame>
    <description>Time required to place laryngeal mask airway will be measured and reported in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion Attempts</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of attempts required for successful insertion of laryngeal mask airway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Attempt Success Rate</measure>
    <time_frame>4 hours</time_frame>
    <description>Percent of laryngeal mask airway placements that are successful upon first attempt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of Insertion</measure>
    <time_frame>4 hours</time_frame>
    <description>The clinician who places the laryngeal mask airway will be asked to rate ease of insertion on a four point rating scale: 1, no resistance; 2, mild resistance; 3, moderate resistance; and 4, inability to place device. Outcome will be reported as the mean score per group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mid-Case Adjustments</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of adjustments made to laryngeal mask airway following insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sore Throat</measure>
    <time_frame>8 hours, 24 hours</time_frame>
    <description>Participants will be asked upon discharge from recovery room (approximately 8 hours post surgery) to rate the soreness of their throat on a numerical rating scale of 0-10 (0 being no soreness and 10 being maximum imaginable soreness). Participants will be asked to rate throat soreness again via phone call approximately 24 hours after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood staining of Laryngeal Mask Airway</measure>
    <time_frame>4 hours</time_frame>
    <description>Upon removal, staff will observe the laryngeal mask airway for the presence of blood and report a yes or no value. Number of devices with blood staining will be reported per group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Anesthesia</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Igel Larnygeal Mask Airway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive the I-Gel Laryngeal Mask Airway for airway maintenance during general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambu Auragain Laryngeal mask airway</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 will receive the Ambu Auragain Laryngeal Mask Airway for airway maintenance during general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-Gel Laryngeal Mask Airway</intervention_name>
    <description>The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.</description>
    <arm_group_label>Igel Larnygeal Mask Airway</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu Auragain Laryngeal Mask Airway</intervention_name>
    <description>The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.</description>
    <arm_group_label>Ambu Auragain Laryngeal mask airway</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - undergoing outpatient ambulatory surgery under general anesthesia that is amenable to
        using a laryngeal mask airway

        Exclusion Criteria:

          -  non-English speaking patients

          -  patients with abnormal airway anatomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Hutchins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Hutchins, MD</last_name>
    <phone>612-624-9990</phone>
    <email>hutc0079@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonah Pearson</last_name>
    <phone>612-625-6659</phone>
    <email>pears731@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacob Hutchins, MD</last_name>
      <phone>612-624-9990</phone>
      <email>hutc0079@umn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

